Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.

Matthew Greenhawt*, Sayantani B. Sindher, Julie Wang, Michael Osullivan, George Du Toit, Edwin H. Kim, Deborah Albright, Sara Anvari, Nicolette Arends, Peter D. Arkwright, Philippe Begin, Katharina Blumchen, Thierry Bourrier, Terri Brown-Whitehorn, Heather Cassell, Edmond S. Chan, Christina E. Ciaccio, Antoine Deschildre, Amandine Divaret-Chauveau, Stacy L. DorrisMorna J. Dorsey, Thomas Eiwegger, Michel Erlewyn-Lajeunesse, David M. Fleischer, Lara S. Ford, Maria Garcia-Lloret, Lisa Giovannini-Chami, Jonathan O. Hourihane, Nicola Jay, Stacie M. Jones, Leigh Ann Kerns, Kirsten M. Kloepfer, Stephanie Leonard, Guillaume Lezmi, Jay A. Lieberman, Jeanne Lomas, Melanie Makhija, Christopher Parrish, Jane Peake, Kirsten P. Perrett, Daniel Petroni, Wolfgang Pfutzner, Jacqueline A. Pongracic, Patrick Quinn, Rachel G. Robison, Georgiana Sanders, Lynda Schneider, Hemant P. Sharma, Juan Trujillo, Paul J. Turner, Katherine Tuttle, Julia E. Upton, Pooja Varshney, Brian P. Vickery, Christian Vogelberg, Brynn Wainstein, Robert A. Wood, Katharine J. Bee, Dianne E. Campbell, Todd D. Green, Rihab Rouissi, Aurelie Peillon, Henry T. Bahnson, Timothee Bois, Hugh A. Sampson, A. Wesley Burks

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

41 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.'. Together they form a unique fingerprint.

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science